Help patients learn how to save on their NovoLog® prescription

CO-PAY CARD

Signing up for the Novo Nordisk Instant Savings Card allows eligible patients to pay as little as:

Check mark icon

$25 for NovoLog® and each refill for up to 2 yearsa

Check mark icon

$20 for another Novo Nordisk product and each refill for up to 2 years and be eligible to receive 1 FREE box of Novo Nordisk needlesa

Direct your patients to NovoLog.com for details on how to request a Savings Card.

aEligibility and other restrictions apply

Fiasp® (insulin aspart injection) 100 U/mL

Consider Fiasp® for adult patients

Fiasp® has the same co-pay offer and similar coverage to NovoLog®. Check to see if your patients are covered.

Get information ►

primary_msg

FORMULARY COVERAGE

NovoLog® has broad formulary coverage to help reach more lives1,b,c

The formulary tool lets you quickly scan NovoLog® coverage for various health plans in your area.d

Loading...

bFormulary data are provided by Fingertip Formulary® and are current as of April 2018. Because formularies do change and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage for individual patients. © 2018 Fingertip Formulary. All rights reserved.

cManaged care plans only. Does not include Medicaid and Medicare Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative costs. Formulary status is subject to change. Multiple products within the same therapeutic class may be considered preferred and on the same tier.

dFormulary status is believed to be accurate at the time of update but cannot be guaranteed.

This information should not be used to make efficacy or safety comparisons between or among mentioned products.

secondary_msg

BENEFIT VERIFICATION

Confirm your patients’ coverage

Find out if your patient’s insurance plan covers NovoLog® and calculate their co-pay. Your patient’s pharmacy prescription card information may be needed.

Verify benefits

tertiary_msg

Complimentary samples of NovoLog® are available

Request samples ►

Selected Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased.

NovoLog® (insulin aspart injection) 100 U/mL Indications and Usage

NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 

Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. 
  • Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. 
  • To avoid medication errors and accidental mix-ups between NovoLog® and other insulin products, instruct patients to always check the insulin label before injection. 
  • Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®. 
  • As with all insulins, NovoLog® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death.  Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. 
  • Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

NovoLog® continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent. 

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age. 
  • Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments. 

Please click here for Prescribing Information.

 

Reference:

  1. Fingertip Formulary: April 2018.